Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Overview
Instil Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative cell therapies for the treatment of solid tumor cancers. The company specializes in harnessing autologous tumor infiltrating lymphocytes (TIL), a breakthrough approach in immunotherapy, to develop targeted treatments for cancer patients. By leveraging a patient’s own immune cells, Instil Bio aims to combat malignancies with a high degree of specificity and reduced off-target effects.
Core Business and Technology
At the heart of Instil Bio's business is its pioneering work in cell therapy. The company extracts T cells directly from a patient’s tumor, expands them ex vivo, and then reinfuses these activated cells back into the patient. This process not only amplifies the natural tumor-fighting capabilities of T cells but also provides a highly personalized treatment option. In addition, Instil Bio is developing a next-generation class of genetically engineered TIL therapies using its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform. This innovative technology enhances the specificity and effectiveness of TILs by modifying them to better recognize and target tumor-associated antigens present in various solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, uterine cancer, and renal cancer.
Clinical Development and Pipeline
Instil Bio operates at the forefront of clinical research with a robust pipeline of novel therapies. The company is advancing its lead TIL candidate into planned registrational studies and also exploring first-in-human trials of its next-generation engineered TIL. The clinical strategy is designed to address significant unmet medical needs, with a focused approach on tumors that historically have limited treatment options. The incorporation of rigorous manufacturing and quality control processes ensures that each therapy is developed to the highest clinical standards.
Manufacturing and Global Operations
Instil Bio has established a strong operational presence with cutting-edge manufacturing and research facilities located in the Greater Los Angeles area and Manchester, UK. This geographic diversity not only facilitates compliance with rigorous regulatory environments but also positions the company strategically in global markets. The proprietary manufacturing expertise is a core asset, allowing for scalable and reliable production of TIL therapies, which is critical for advancing clinical trials and future commercialization.
Strategic Collaborations and Industry Position
Instil Bio collaborates with key industry players and is backed by premier global institutional investors. Its strategic partnership with companies like ImmuneOnco underscores its commitment to innovation and efficient clinical development. These collaborations enhance the company's ability to bring sophisticated therapies, such as its differentiated PD-L1xVEGF bispecific antibody, to market. This bispecific molecule, which leverages enhanced antibody-dependent cellular cytotoxicity (ADCC) and a novel VEGF trap, further diversifies Instil Bio's portfolio by combining immunomodulatory functions with targeted therapy for solid tumors.
Market Significance and Value Proposition
Instil Bio occupies an important niche in the oncology market by focusing on cell-based therapies that offer a high degree of personalization. The company’s dual approach—combining traditional TIL therapy with genetically engineered cell therapy—positions it uniquely among clinical-stage biopharmaceutical companies. By addressing a spectrum of cancers with significant unmet clinical needs, Instil Bio contributes to the evolution of precision medicine in oncology. The high level of expertise within its management team, supported by a solid track record in the cell therapy domain, reinforces its standing as a trusted entity in the biopharma industry.
Research and Development Focus
The company’s emphasis on research and development is evident in its continuous pursuit of therapeutic innovation. With an eye on both refining existing processes and exploring novel genetic engineering techniques, Instil Bio remains committed to elevating the efficacy and accessibility of its therapies. The work carried out within its advanced research facilities yields valuable insights into tumor immunology, further informing the development of next-generation cancer treatments.
Conclusion
Instil Bio, Inc. exemplifies a modern approach to oncology treatment that integrates personalized medicine with advanced cell technology. Its commitment to clinical excellence, robust manufacturing capabilities, and strategic collaborations with industry leaders underpins its role in reshaping therapeutic paradigms in cancer treatment. By continuously pushing the boundaries of cell therapy and genetic engineering, Instil Bio maintains a significant and enduring presence in the rapidly evolving biopharmaceutical landscape.
Instil Bio (TIL) has reported its Q4 and full year 2024 financial results. The company ended 2024 with $115.1 million in total cash and equivalents, down from $175.0 million in 2023. Their cash runway is expected to extend beyond 2026.
Key clinical developments include anticipated data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China during 1H 2025, with additional safety data expected from approximately 100 patients across multiple solid tumors. ImmuneOnco plans to begin enrolling first-line NSCLC patients in Q2 2025 for a combination therapy trial with chemotherapy, with initial data expected in 2H 2025.
Financial highlights show reduced losses, with full-year 2024 net loss per share at $11.39, improved from $24.00 in 2023. R&D expenses decreased to $11.8 million in 2024 from $39.6 million in 2023, while G&A expenses slightly decreased to $44.2 million from $47.6 million.
Instil Bio (NASDAQ: TIL) announced significant progress in the clinical development of IMM2510/SYN-2510, a PD-L1xVEGF bispecific antibody, in China through its collaborator ImmuneOnco. The first patient has been dosed in a Phase 1b/2 clinical trial combining IMM2510/SYN-2510 with chemotherapy for advanced non-small cell lung cancer (NSCLC) patients.
ImmuneOnco plans to present initial clinical data from the trial, including first-line NSCLC patient data, in the second half of 2025. Instil Bio also plans to initiate its own U.S. clinical trial of SYN-2510/IMM2510 combined with chemotherapy for first-line NSCLC patients in the second half of 2025, pending regulatory approvals.
Instil Bio reported Q3 2024 financial results and corporate updates. The company licensed SYN-2510, a PD-L1xVEGF bispecific antibody, for global ex-China development. Cash position was $122.9M as of September 30, 2024, expected to fund operations beyond 2026. Q3 net loss per share was $3.54. Clinical updates include anticipated data from ImmuneOnco for SYN-2510 in 1H 2025, planned Phase 1b/2 studies in NSCLC and TNBC, and targeted U.S. clinical study initiation in 2H 2025.
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals have announced their global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Key points include:
1. Phase 1b/2 trials of IMM2510/SYN-2510 + chemotherapy in first-line NSCLC to start in China by late 2024
2. Phase 1b/2 trials in first-line TNBC to begin in China by early 2025
3. US IND submission for SYN-2510 planned for late 2024, starting with Phase 2 monotherapy trial in second-line NSCLC
4. Potential global Phase 3 trials in first-line NSCLC and TNBC based on positive proof-of-concept data
This strategy aims to address significant unmet medical needs in NSCLC and TNBC patients, potentially improving the current standard of care.
Instil Bio (Nasdaq: TIL) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. In-licensed SYN-2510 and SYN-27M, potentially best-in-class therapeutics, from ImmuneOnco.
2. Executed a 15-year lease of cell therapy manufacturing facility to AstraZeneca, with initial base rent exceeding $7.5 million annually.
3. Cash, cash equivalents, marketable securities, and long-term investments totaled $152.6 million as of June 30, 2024.
4. Q2 2024 R&D expenses were $2.9 million, down from $8.5 million in Q2 2023.
5. Net loss per share for Q2 2024 was $2.29, improved from $2.87 in Q2 2023.
6. Cash runway expected to extend beyond 2026.
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement for the development of two promising antibodies: IMM2510 and IMM27M. IMM2510 is a potentially best-in-class PD-L1xVEGF bispecific antibody that has shown multiple responses in advanced solid tumors, including in patients who previously failed PD-1 inhibitors. IMM27M is a novel next-generation anti-CTLA-4 antibody designed to enhance efficacy and reduce toxicity compared to first-generation anti-CTLA-4 antibodies.
Under the agreement, Instil Bio will receive global development and commercialization rights for both antibodies outside of Greater China, while ImmuneOnco retains rights in Greater China. The deal includes an upfront payment and potential near-term payments of up to $50 million, with additional milestones exceeding $2 billion plus royalties on global ex-China sales.
Instil Bio, Inc. reported its first quarter 2024 financial results, showcasing a cash balance of $161.5 million, expected to fund operations beyond 2026. The company highlighted successful feasibility studies, plans for a potential trial in non-small cell lung cancer, and exploring new therapeutic candidates. Research and development expenses decreased, while general and administrative expenses remained stable. Non-GAAP net loss per share improved from the previous year.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
What is the primary focus of Instil Bio, Inc.?
How do TIL therapies work in cancer treatment?
What distinguishes Instil Bio's approach to cell therapy?
Which types of cancer are targeted by Instil Bio's therapies?
What role do collaborations play in Instil Bio's strategy?
Where are Instil Bio's manufacturing and research facilities located?
What is the significance of the CoStAR platform?
How is Instil Bio positioned within the oncology market?
